Trubion Announces Dates for Third Quarter and Nine Months 2009 Earnings Conference Call

SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that it plans to issue earnings results for its third quarter and nine months ended Sept. 30, 2009, after the close of market on Nov. 5, 2009. The company's earnings conference call will take place Nov. 5, 2009 at 2 p.m. Pacific Time, 5 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

The live event will be available for viewing on Trubion's website at http://investors.trubion.com.

Third Quarter and Nine Months 2009 Earnings Conference Call: 2 p.m. PST / 5 p.m. EST, Nov. 5, 2009

Trubion will host a conference call and webcast to discuss its third quarter and nine months ended Sept. 30, 2009 financial results and provide an update on business activities. The call will be held Nov. 5 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's website at http://investors.trubion.com, or by calling (703) 639-1156 or (866) 238-0637. A replay of the discussion will be available beginning at 8 p.m. Eastern Time from Trubion's website or by calling (703) 925-2533 or (888) 266-2081 and entering 1408250. The telephone replay will be available until midnight, Nov. 11, 2009.

About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet Biotech collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm

TRBN-G

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals Inc.
    (206) 838-0500

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788